The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios

2016 ◽  
Vol 43 (13) ◽  
pp. 2453-2455 ◽  
Author(s):  
Sandip Basu ◽  
Vikas Ostwal
Keyword(s):  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Combined Chemotherapy ◽  
Peptide Receptor ◽  
Metastatic Neuroendocrine Tumor

scholarly journals Efficacy of Peptide Receptor Radionuclide Therapy in a United States–Based Cohort of Metastatic Neuroendocrine Tumor Patients

Pancreas ◽  
2017 ◽  
Vol 46 (9) ◽  
pp. 1121-1126 ◽  
Author(s):  
Bryson W. Katona ◽  
Giorgio A. Roccaro ◽  
Michael C. Soulen ◽  
Yu-Xiao Yang ◽  
Bonita J. Bennett ◽  
...  
Keyword(s):  
United States ◽  
Neuroendocrine Tumor ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Tumor Patients ◽  
Peptide Receptor ◽  
Metastatic Neuroendocrine Tumor

scholarly journals A Case of Primary Hepatic Neuroendocrine Tumor and Literature Review

2021 ◽  
pp. 90-97
Author(s):  
Pak Chiu Wong ◽  
Wong Hoi She ◽  
Ui Soon Khoo ◽  
Tan To Cheung
Keyword(s):  
Liver Resection ◽  
Neuroendocrine Tumor ◽  
Preoperative Diagnosis ◽  
Radionuclide Therapy ◽  
Tumor Recurrence ◽  
Peptide Receptor Radionuclide Therapy ◽  
Rare Tumor ◽  
Major Liver Resection ◽  
Peptide Receptor ◽  
Primary Hepatic Neuroendocrine Tumor

We report an unusual presentation of primary hepatic neuroendocrine tumor which was initially misdiagnosed as intrahepatic cholangiocarcinoma. The diagnosis was only revealed after a major liver resection by histopathology. With adjuvant lanreotide injection, the patient survived for more than 16 months after the operation without tumor recurrence. Diagnosis of this rare tumor has been a major challenge and we emphasize the importance of a preoperative diagnosis. Surgical resection remains the mainstay for curative treatment, while peptide receptor radionuclide therapy is an emerging treatment option which has provided promising results.

scholarly journals Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor

Oncotarget ◽  
2018 ◽  
Vol 9 (37) ◽  
pp. 24693-24706 ◽  
Author(s):  
Nupur K. Purohit ◽  
Rashmi G. Shah ◽  
Samuel Adant ◽  
Michael Hoepfner ◽  
Girish M. Shah ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Cells ◽  
Radionuclide Therapy ◽  
Parp Inhibitor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor
Sign in / Sign up

Export Citation Format

Share Document